trending Market Intelligence /marketintelligence/en/news-insights/trending/ZIvLqv6WJQH0wMKxWLfPvQ2 content esgSubNav
In This List

Getinge to acquire Applikon Biotechnology for 840M Swedish kronor

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Getinge to acquire Applikon Biotechnology for 840M Swedish kronor

Getinge AB agreed to acquire privately held Dutch company Applikon Biotechnology BV for 840 million Swedish kronor in cash.

Under the agreement, the Swedish healthcare company will purchase all of Applikon Biotechnology's outstanding common shares. Getinge could pay up to 630 million kronor in additional earnout fees in 2021-2022 upon the achievement of certain earnings performance in 2020-2021.

Getinge said it does not expect any material impact on its 2020 earnings.

The acquisition, which will be financed through debt, is expected to close during the first quarter of 2020.

Deutsche Bank is Getinge's exclusive financial adviser and NautaDutilh the legal adviser for the deal.

As of Dec. 18, US$1 was equivalent to 9.42 Swedish kronor.